Recent Developments in UK Tissue Engineering
スポンサーリンク
概要
- 論文の詳細を見る
In recent years confidence has grown in the marketed tissue engineered products. These first-generation therapies such as Dermagraft, TransCyte, Integra, Apligraf, Alloderm, and Biobrane are relatively simple products delivering a single cell type or acellular matrix for dermal repair. Second-generation tissue engineered devices may encompass therapies with complex stratified tissues, intelligent/resorbable/active scaffolds and multiple-gene therapy, all combining to improve clinical outcomes for both internal and external tissue repair. Short to medium term target tissues include repair of the heart, ligament, tendon, cartilage and bone, Ultimately, almost every tissue in the body may be subject to tissue engineering therapy. However, the clinical realisation of tissue engineered products, to date, has proved difficult. Both industry and academia in the UK must set itself the challenge to overcome the problems of cell sourcing, cell expansion, cost reduction, quality control, regulation and clinical outcome. To help achieve this, the coordinated development of UK tissue engineering is presently being achieved through the newly established "UK Center for Tissue Engineering" University of Manchester and the University of Liverpool which is led by Professor Tim Hardingham, Manchester, and Prof David Williams, Liverpool. In this review, topics such as recent regulatory issues, industrial objectives and academic challenges will be described, as well as providing background information regarding leaders in the field, academic groups, companies, government initiatives and the future prospects for UK tissue engineering.
- 一般社団法人日本機械学会の論文